Abstract：
OBJECTIVE: Subacute thyroiditis (SAT) is a transient inflammatory disorder of the thyroid gland with a possible viral etiology. We conducted this study to estimate the pooled prevalence of thyroid autoantibodies in SAT patients. This question arose due to the varying reports on the positivity rates of thyroid autoantibodies among SAT patients.
METHODS: We searched PubMed, Embase, Scopus, and Web of Science from their inception until March 25th, 2023. Observational studies reporting the positivity rate of thyroid autoantibodies for more than ten patients were included. We used the Joanna Briggs Institute\'s (JBI) critical appraisal checklist to assess the quality of the included studies. Pooled prevalence estimates with 95% confidence intervals were calculated using the random effects model. Subgroup analyses were performed to find sources of heterogeneity.
RESULTS: Out of 1373 identified records, 32 studies involving 2348 SAT patients were included in our study. Thyroglobulin antibody (TgAb) and thyroid peroxidase antibody (TPOAb) were positive in 22.8% and 12.2% of patients, respectively. The Study design, mean erythrocyte sedimentation rate and mean thyroid-stimulating hormone of patients were identified as sources of heterogeneity. As our secondary objectives, we found a recurrence rate of 14.7% and permanent hypothyroidism in 11.6% of patients.
CONCLUSIONS: The results of our study revealed a low TPOAb positivity rate in SAT patients, consistent with its non-autoimmune etiology. The TgAb positivity rate in SAT patients was higher than that of the general population, possibly explained by the transient release of thyroglobulin into the bloodstream during the thyrotoxic phase, leading to subsequent TgAb production. Furthermore, our findings demonstrate a notable recurrence rate and permanent hypothyroidism among SAT patients, highlighting the importance of ongoing follow-up care.
METHODS: We searched PubMed, Embase, Scopus, and Web of Science from their inception until March 25th, 2023. Observational studies reporting the positivity rate of thyroid autoantibodies for more than ten patients were included. We used the Joanna Briggs Institute\'s (JBI) critical appraisal checklist to assess the quality of the included studies. Pooled prevalence estimates with 95% confidence intervals were calculated using the random effects model. Subgroup analyses were performed to find sources of heterogeneity.
RESULTS: Out of 1373 identified records, 32 studies involving 2348 SAT patients were included in our study. Thyroglobulin antibody (TgAb) and thyroid peroxidase antibody (TPOAb) were positive in 22.8% and 12.2% of patients, respectively. The Study design, mean erythrocyte sedimentation rate and mean thyroid-stimulating hormone of patients were identified as sources of heterogeneity. As our secondary objectives, we found a recurrence rate of 14.7% and permanent hypothyroidism in 11.6% of patients.
CONCLUSIONS: The results of our study revealed a low TPOAb positivity rate in SAT patients, consistent with its non-autoimmune etiology. The TgAb positivity rate in SAT patients was higher than that of the general population, possibly explained by the transient release of thyroglobulin into the bloodstream during the thyrotoxic phase, leading to subsequent TgAb production. Furthermore, our findings demonstrate a notable recurrence rate and permanent hypothyroidism among SAT patients, highlighting the importance of ongoing follow-up care.
摘要：
目的：亚急性甲状腺炎（SAT）是一种短暂的甲状腺炎症性疾病，可能是病毒性病因。我们进行了这项研究来估计SAT患者甲状腺自身抗体的合并患病率。这个问题的出现是由于SAT患者中甲状腺自身抗体阳性率的不同报道。
方法：我们搜索了PubMed，Embase,Scopus,和WebofScience从成立到3月25日，2023年。纳入了报告10例以上患者甲状腺自身抗体阳性率的观察性研究。我们使用JoannaBriggs研究所（JBI）的关键评估清单来评估纳入研究的质量。使用随机效应模型计算具有95%置信区间的合并患病率估计值。进行亚组分析以发现异质性的来源。
结果：在1373个确定的记录中，我们的研究包括了32项涉及2348名SAT患者的研究。甲状腺球蛋白抗体(TgAb)和甲状腺过氧化物酶抗体(TPOAb)分别为22.8%和12.2%的患者,分别。研究设计，患者的平均红细胞沉降率和平均促甲状腺激素被确定为异质性来源.作为我们的次要目标，我们发现11.6%的患者复发率为14.7%,永久性甲状腺功能减退.
结论：我们的研究结果表明，SAT患者的TPOAb阳性率较低，符合其非自身免疫性病因。SAT患者的TgAb阳性率高于一般人群，这可能是由于在甲状腺毒性阶段甲状腺球蛋白短暂释放到血液中，导致随后的TgAb生产。此外，我们的研究结果表明，SAT患者中有明显的复发率和永久性甲状腺功能减退症，强调持续后续护理的重要性。
方法：我们搜索了PubMed，Embase,Scopus,和WebofScience从成立到3月25日，2023年。纳入了报告10例以上患者甲状腺自身抗体阳性率的观察性研究。我们使用JoannaBriggs研究所（JBI）的关键评估清单来评估纳入研究的质量。使用随机效应模型计算具有95%置信区间的合并患病率估计值。进行亚组分析以发现异质性的来源。
结果：在1373个确定的记录中，我们的研究包括了32项涉及2348名SAT患者的研究。甲状腺球蛋白抗体(TgAb)和甲状腺过氧化物酶抗体(TPOAb)分别为22.8%和12.2%的患者,分别。研究设计，患者的平均红细胞沉降率和平均促甲状腺激素被确定为异质性来源.作为我们的次要目标，我们发现11.6%的患者复发率为14.7%,永久性甲状腺功能减退.
结论：我们的研究结果表明，SAT患者的TPOAb阳性率较低，符合其非自身免疫性病因。SAT患者的TgAb阳性率高于一般人群，这可能是由于在甲状腺毒性阶段甲状腺球蛋白短暂释放到血液中，导致随后的TgAb生产。此外，我们的研究结果表明，SAT患者中有明显的复发率和永久性甲状腺功能减退症，强调持续后续护理的重要性。
